ÌÇÐÄvlog´«Ã½

Hypoxia Treatment Market Analysis

The Hypoxia Treatment Market is expected to grow at a registered CAGR of 3.5% during the forecast period.

Coronavirus disease-2019 (COVID-19) produces severe hypoxemia, exacerbating the COVID-19 damage. Furthermore, the precise impact of hypoxia on COVID-19 patients is uncertain. Early on in the COVID-19 infection, some COVID-19 patients develop a condition known as "silent hypoxia," and it has been observed that hypoxia may aggravate the infection and exacerbate lung cell destruction. According to the study titled "Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous? A retrospective cohort study" published in the Lung India in June 2022, around 32% to 65% of COVID-19 patients developed silent hypoxia. Additionally, according to the study titled "Oxygen therapy strategies and techniques to treat hypoxia in COVID-19 patients" published in the European Review of Medical and Pharmaceutical Science, in May 2020, early-stage oxygen therapy has the potential to treat hypoxia in COVID-19 patients As a result, the market growth is expected to impact by the rise in demand for oxygen therapy among COVID-19 patients.

The market is being driven by both an increase in research and development activity by the pharmaceutical industry and an increase in the prevalence of hypoxia. According to the study titled "The prevalence of hypoxemia among pediatric and adult patients presenting to healthcare facilities in low- and middle-income countries: protocol for a systematic review and meta-analysis" published in the Systematic Review in March 2020, the prevalence of hypoxemia in children under the age of 12 ranged from 2-23% in the low and middle incomes countries. Therefore, the increasing prevalence of hypoxia is anticipated to increase the demand for therapeutic options in the management of diseases, driving up the market's growth.

Additionally, rising R&D activity is anticipated to support market expansion over the forecast period. According to the study titled "Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study " published in the Critical Care in February 2021, an efficient interface for administering noninvasive continuous positive airway pressure (CPAP) is a helmet. Patients might profit from helmet CPAP as a life-saving treatment to increase survival. Moreover, growing research and development spending is expected to boost the market growth. As per the September 2020 update by the Pharmaceutical Research and Manufacturers of America (PhRMA), the PhRMA members had invested nearly USD 83 billion in R&D activities in 2020. Furthermore, as per the same source, more than 260 vaccines are in the pipeline by biopharmaceutical companies for various diseases, including COVID-19, as per PhRMA, 2020.

Thus, all aforementioned factors such as the rising prevalence of hypoxia and growing research and development activity expected to boost the market growth. However, stringent government regulation coupled with the availability of substitute products may restrain the market growth over the forecast period.

Hypoxia Treatment Industry Segmentation

Hypoxia is a condition in which the body's tissues do not have access to enough oxygen to maintain healthy homeostasis. This can be caused by either insufficient blood flow to the tissues or low blood oxygen levels (hypoxemia). Acute, chronic, or acute and chronic forms of hypoxia can be present and range in severity from mild to severe. The Hypoxia Treatment Market is Segmented By Type (Hypoxic Hypoxia, Anaemic Hypoxia, Stagnant Hypoxia, and Histotoxic Hypoxia), Disease Type (Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, Sleep, Asthma, and Others), End User (Hospitals/Clinics and Others) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments.